43 results
Keyword Bonviva Remove keyword
-
List item
Human medicine European public assessment report (EPAR): Bonviva
ibandronic acid, Osteoporosis, Postmenopausal
Date of authorisation: 23/02/2004, Revision: 28, Authorised, Last updated: 29/03/2021Bonviva Musculoskeletal Diseases Bone … assessment report (EPAR) for Bonviva. It explains how the The committee … the conditions of use for Bonviva. What is Bonviva? Bonviva is a medicine that contains … -
List item
Human medicine European public assessment report (EPAR): Ibandronic Acid Teva
ibandronic acid, Breast Neoplasms; Neoplasm Metastasis; Fractures, Bone; Osteoporosis, Postmenopausal
Date of authorisation: 17/09/2010,
, Revision: 11, Authorised, Last updated: 06/09/2021
Acid Teva are Bondronat and Bonviva. What is Ibandronic Acid Teva … bioequivalent to Bondronat and Bonviva. Therefore, the CHMP’s view … that, as for Bondronat and Bonviva, the benefit outweighs the … -
List item
Human medicine European public assessment report (EPAR): Ibandronic acid Accord
ibandronic acid, Wounds and Injuries; Breast Diseases; Neoplastic Processes; Calcium Metabolism Disorders; Water-Electrolyte Imbalance
Date of authorisation: 18/11/2012,, Revision: 13, Authorised, Last updated: 12/04/2022
Accord are Bondronat and Bonviva. How is Ibandronic acid Accord … medicines, Bondronat and Bonviva, and do not need to be repeated … comparable to Bondronat and Bonviva. Therefore, the Agency’s … -
List item
Press release: European Medicines Agency concludes class review of bisphosphonates and atypical fractures
CHMP, Last updated: 15/04/2011Adrovance, Bondenza, Bondronat, Bonviva, Fosavance, Ibandronic acid … Adrovance, Bondenza, Bondronat, Bonviva, Fosavance, Ibandronic acid … -
List item
Press release: European Medicines Agency finalises review of medicines concerned by Roche pharmacovigilance inspection
Last updated: 19/11/2013Avastin, Bondenza, Bondronat, Bonviva, Cellcept, Fuzeon, Heceptin … Avastin, Bondenza, Bondronat, Bonviva, Cellcept, Fuzeon, Heceptin … -
List item
Press release: European Medicines Agency starts infringement procedure to investigate Roche's alleged non-compliance with pharmacovigilance obligations
Last updated: 23/10/2012Roche): EPAR Bondronat: EPAR Bonviva: EPAR CellCept: EPAR Fuzeon … Avastin, Bondenza, Bondronat, Bonviva, Cellcept, Fuzeon, Herceptin … -
List item
Referral: Bisphosphonates
alendronic acid, clodronic acid, etidronic acid, ibandronic acid, neridronic acid, pamidronic acid, risedronic acid, tiludronic acid, zoledronic acid, associated names: Actonel, Aredia, Bonefos, Didronel, Fosamax, Nerixia, Skelid, Article 31 referrals
Status: European Commission final decision, opinion/position date: 14/04/2011, EC decision date: 13/07/2011, Last updated: 28/10/2011Bondenza: EPAR Bondronat: EPAR Bonviva: EPAR Fosavance: EPAR Ibandronic … zoledronic acid), Bondenza, Bonviva, Bondronat and Ibandronic … Adrovance, Bondenza, Bondronat, Bonviva, Fosavance, Ibandronic acid … -
List item
Human medicine European public assessment report (EPAR): Bondronat
ibandronic acid, Hypercalcemia; Breast Neoplasms; Neoplasm Metastasis; Fractures, Bone
Date of authorisation: 25/06/1996, Revision: 31, Authorised, Last updated: 24/03/2021 -
List item
Press release: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP), 21-24 June 2010
CHMP, Last updated: 25/06/2010Teva 150 mg* is a generic of Bonviva. … 150 mg* is a generic of Bonviva. • Telmisartan Actavis … -
List item
Human medicine European public assessment report (EPAR): Invirase
saquinavir, HIV Infections
Date of authorisation: 03/10/1996, Revision: 48, Authorised, Last updated: 25/11/2021 -
List item
Human medicine European public assessment report (EPAR): Bondenza (previously Ibandronic Acid Roche)
ibandronic acid, Osteoporosis, Postmenopausal
Date of authorisation: 23/02/2004, Revision: 16, Withdrawn, Last updated: 13/05/2013 -
List item
Download medicine data
Last updated: 02/12/2021 -
List item
News: European Commission closes infringement procedure against Roche
Last updated: 15/12/2017Avastin, Bondenza, Bondronat, Bonviva, Cellcept, Fuzeon, Herceptin … -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 8-11 February 2016
European Medicines Agency, London, UK, from 08/02/2016 to 11/02/2016, Last updated: 13/03/2014 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 7-10 September 2015
European Medicines Agency, London, UK, from 07/09/2015 to 10/09/2015, Last updated: 13/03/2014 -
List item
Press release: European Medicines Agency: Committee for Medicinal Products for Human Use 23-26 January 2006
CHMP, Last updated: 27/01/2006Bondenza (ibandronic acid) and Bonviva (ibandronic acid) 3mg/3ml … for injection. Bondenza and Bonviva were first authorised in … -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 4-7 February 2013
European Medicines Agency, London, UK, from 04/02/2013 to 07/02/2013, Last updated: 02/06/2012 -
List item
News: CHMP re-elects its Chair and Vice-Chair
Last updated: 02/07/2010Teva 150 mg is a generic of Bonviva. • Telmisartan Actavis … -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 7-10 January 2013
European Medicines Agency, London, UK, from 07/01/2013 to 10/01/2013, Last updated: 02/06/2012 -
List item
Committee for Medicinal Products for Human Use (CHMP): 21-24 June 2010
European Medicines Agency, London, UK, from 21/06/2010 to 24/06/2010, Last updated: 16/02/2010Teva 150 mg is a generic of Bonviva. • Telmisartan Actavis … -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 4-8 July 2016
European Medicines Agency, London, UK, from 04/07/2016 to 08/07/2016, Last updated: 04/07/2016 -
List item
Press release: Committee for Proprietary Medicinal Products (CPMP) 18th plenary meeting
Last updated: 18/07/1996Bondronat (ibandronic acid) and Bonviva (ibandronic acid) (for further … -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 2-5 September 2013
European Medicines Agency, London, UK, from 02/09/2013 to 05/09/2013, Last updated: 02/07/2012 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 9-12 March 2015
European Medicines Agency, London, UK, from 09/03/2015 to 12/03/2015, Last updated: 13/03/2014 -
List item
Article 5(3) opinions
Last updated: 10/01/2022